Is Morphic Holding a Buy?

Is Morphic Holding a Buy?

On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its experimental therapy, MORF-057. Integrins are small molecules that are responsible for cellular adhesion and signaling. Right now, most of the company's candidates are in the preclinical stages of development.